logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 11857601 B1

PDFFull Text
Date of Patent:
Jan. 02, 2024

Filed:

Mar. 18, 2021

Pharmaceutical composition for cancer treatment comprising fusion protein including il-2 protein and cd80 protein and anticancer drug

Applicant:

Gi Innovation, Inc., Seoul, KR;

Inventors:

Myung Ho Jang, Seoul, KR;

Su Youn Nam, Seoul, KR;

Young Jun Koh, Seoul, KR;

Assignee:

GI INNOVATION, INC., Seoul, KR;

Attorney:

Sughrue Mion, PLLC

Primary Examiner:

Elly-Gerald Stoica

Int. Cl.
CPC ...
A61P 35/00 (2006.01); A61K 33/243 (2019.01); A61K 31/337 (2006.01); A61K 31/4439 (2006.01); A61K 31/444 (2006.01); A61K 31/47 (2006.01); A61K 31/4709 (2006.01); A61K 31/502 (2006.01); A61K 31/5025 (2006.01); A61K 31/506 (2006.01); A61K 31/519 (2006.01); A61K 31/708 (2006.01); A61K 38/17 (2006.01); A61K 39/395 (2006.01); A61K 45/06 (2006.01); A61K 38/20 (2006.01);
U.S. Cl.
CPC ...
A61K 38/2013 (2013.01); A61K 31/337 (2013.01); A61K 31/444 (2013.01); A61K 31/4439 (2013.01); A61K 31/47 (2013.01); A61K 31/4709 (2013.01); A61K 31/502 (2013.01); A61K 31/506 (2013.01); A61K 31/5025 (2013.01); A61K 31/519 (2013.01); A61K 31/708 (2013.01); A61K 33/243 (2019.01); A61K 38/1774 (2013.01); A61K 39/3955 (2013.01); A61K 45/06 (2013.01); A61P 35/00 (2018.01);
Abstract

A pharmaceutical composition containing, as active ingredients, a fusion protein including an IL-2 protein and a CD80 protein, and an anticancer agent is disclosed. A fusion protein including a CD80 fragment, an immunoglobulin Fc, and an IL-2 variant, can activate immune cells such as natural killer cells, and at the same time, can control the immune cell regulatory activity of regulatory T cells. In addition, when an anticancer agent is administered in combination with the fusion protein, cancer can be effectively inhibited. Therefore, a pharmaceutical composition containing, as active ingredients, a fusion protein of an IL-2 protein and a CD80 protein, and an anticancer agent can increase the immune activity in the body and can be effectively utilized not only for cancer but also for an infectious disease, and thus has high industrial potential.

Find Patent Forward Citations

Loading…